Dulaglutide and pregnancy: a comprehensive safety assessment using the <i>ex vivo</i> placenta perfusion and <i>in vitro</i> models.

ABSTRACT: The use of glucagon-like peptide-1 (GLP-1) receptor agonists by young populations is rapidly increasing worldwide, thereby exposing more women of childbearing age. Dulaglutide, a long-acting GLP-1 receptor agonist designed to bind to the neonatal Fc receptor (FcRn) and approved for type 2 diabetes mellitus, reflects this trend. In this study, we wanted to evaluate transplacental passage of dulaglutide and its potential effects on placental function. Transplacental transfer was investigated both with human placenta perfusions, a model for term transfer and expressing FcRn; and with permeability assays across BeWo b30 cell layers, a model for the early pregnancy placental barrier and characterised by negligible FcRn expression. Additional in vitro experiments were performed with human

SUBMITTER: Kuoni S 

PROVIDER: S-EPMC12865208 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature